Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19630784 | 0.88 | LCK (0.51) | LCKCACNA1BCACNA1CCACNA1HDYRK1A | |
| SCHEMBL19630738 | 0.88 | LCK (0.51) | LCKCACNA1BCACNA1CCACNA1H | |
| SCHEMBL19631041 | 0.80 | LCK (0.53) | LCK | |
| SCHEMBL30810269 | 0.80 | LCK (0.44) | LCKCACNA1BCACNA1CCACNA1HDYRK1A | |
| SCHEMBL30810365 | 0.79 | LCK (0.46) | LCKCACNA1BCACNA1CCACNA1HDYRK1A | |
| SCHEMBL19630789 | 0.75 | LCK (0.52) | LCK | |
| SCHEMBL19630788 | 0.75 | LCK (0.52) | LCK | |
| SCHEMBL19630817 | 0.74 | LCK (0.54) | LCKDYRK1A | |
| SCHEMBL19631014 | 0.73 | ALDH1A1 (0.44) | LCKDYRK1ACSNK1D | |
| SCHEMBL19631099 | 0.73 | LCK (0.44) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458454-B1 | 2-HYDROXY-N-(BENZO[D]THIAZOL-2-YL)BENZAMIDE DERIVATIVES AS MITOCHONDRIAL UNCOUPLERS FOR THE TREATMENT OF METABOLIC DISEASES AND CANCER | UNIV RUTGERS (US) | 2021-11-24 | — | — | EP | disclosed |
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2017-11-23 | — | — | US | disclosed |
| WO-2017201313-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | JIN SHENGKAN (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227315-B2 | Mitochondrial uncouplers for treatment of metabolic diseases and cancer | AK2, PC, GLS2 | LCK 1239/4885CACNA1B 3828/4885CACNA1C 2688/4885 |
| US-20170334869-A1 | NOVEL MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | AK2, PC, GLS2 | LCK 1003/4885CACNA1B 3740/4885CACNA1C 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.